Nightingale’s biomarker analysis platform has helped researchers from diverse fields to identify new associations, predict diseases or enhance gene discoveries. Explore what our panels can do for you in your field of research.
To support researchers tackling COVID-19, we will be prioritising studies focused on the pandemic and will be delivering sample analyses at an accelerated rate.
Nightingale’s blood panel holds the potential for accelerating COVID-19 studies as we have a strong track record in risk stratification and assessment of frailty. In these areas, our biomarkers like GlycA have been associated with the risk of hospitalisation and mortality due to systemic and respiratory infection.
Our panel has been used in numerous large-scale studies to gain phenotypic insights where they have found a strong genetic regulation of various Nightingale biomarkers. Thus, it can be helpful in COVID-19-related genetic research.
Also, the blood panel holds the potential to identify individuals at high risk who show severe symptoms and could be hospitalised due to COVID-19 infection. This can help in responding better to later waves of the virus and minimise overall mortality. Our biomarkers also offer potential prognostics applications in hospital settings to identify patients who are most likely to face the worst effects of the disease. Several ongoing studies are already using our platform for this.
Ritchie et al. Cell Systems 2015:1(4);293-301
Deelen et al., NAT COMMUN 2019;10:3346
Locke et al. Nature 2019; Jul 31
Nightingale’s blood panel has been used by numerous CVD researchers globally. By providing a comprehensive coverage of metabolites, our platform can be a powerful tool for studies focusing on disease prediction and risk model development, disease etiology, drug development, translation and combining genomics data with metabolic data.
Our biomarkers include an advanced lipid panel with 14 lipoprotein subclasses, inflammation marker–GlycA along with other key CVD biomarkers, clinically validated biomarkers for fast translation (like clinical LDL-cholesterol, ApoA1 and ApoB) and numerous emerging markers such as fatty acids and amino acids.
Holmes et al. Journal of the American College of Cardiology 2018;71(6):620-32
Kettunen et al. PLoS Biology 2019;17(12):e3000572
Sliz et al. Circulation. 2018;138:2499–2512
Nightingale’s blood and urine panels are a versatile tool for diabetes research. Our blood panel has been used for capturing signals of the earliest metabolic dysregulation associated with diabetes and helped in identifying differences in risk and prevalence of type 2 diabetes among various ethnic groups as it can easily be integrated with genetics data to enhance gene discoveries.
Both the blood and urine panels include amino acids and glycolysis-related metabolites for easy comparison and understanding of molecular mechanisms. In addition, our blood panel also provides inflammation marker GlycA, advanced lipid panel with 14 lipoprotein subclasses and clinically validated biomarkers for fast translation.
Tillin et al. Diabetologia 2015;58(5):968-79
Wang et al. Diabetes Care 2017;40(12):1779-86
Welsh et al. Diabetologia 2018;61(7):1581–91
Nightingale’s metabolic profiling provides a broad overview of the host’s systemic metabolism. This enables exploring new connections between gut microbes, nutrition and different areas of health, and can help to understand the function of gut microbial species. Our platform has been used in published research on gut microbial associations in metabolic syndrome, CVD and pregnancy as well for studying disease progression for inflammatory bowel disease.
In addition, to covering the major biological pathways, our blood and urine analysis also includes biomarkers that are of special interest to gut research; acetate and inflammation biomarker from blood like GlycA, as well as TMAO, dimethylamine and lactate from urine.
ORG ET AL. GENOME BIOLOGY 2017;18:70
Dierckx et al. JCC 2019;13(3):389–394
Röytiö et al. British Journal of Nutrition 2017;118(5):343-352
Nightingale’s metabolic profiling is an excellent tool for various types of studies such as post-prandial studies and interventions searching for links between dietary intake and health outcomes. This insight of metabolite-level changes enhance understanding why certain foods or nutrients associate with diseases in epidemiological studies.
Nightingale’s blood panel covers a vast range of metabolites, such as the detailed lipid subclasses, amino acids, fatty acids, and inflammatory markers that respond to changes in dietary intake. Our novel urine platform includes several metabolites that may prove useful as biomarkers of food and nutrient intake such as proline betaine (fruit and vegetables), TMAO (meat), and sucrose (sugar).
Lehtovirta et al. The Journal of Pediatrics 2018;195:190-198.e3
Michielsen et al. Mol Nutr Food Res. 2019;63(9):e1801095
Beynon et al. 2018;144:1918–1928
Nightingale’s metabolomics data has been used in several studies to identify the connection between metabolic health and ageing. For instance, our blood panel has been used to identify the impact of lifestyle choices on metabolic health and age in older populations. The platform is also suitable for studies focusing on distinct research areas such as menopause and dementia.
Our blood panel includes amino acids and a comprehensive lipid profile providing insights on the changing metabolism and its effect on aging. Our CSF panel consists of several small molecular weight metabolites that overlap with our blood panel, enabling easy comparison between the two circulating systems.
Van de Rest et al. Aging 2016;8(1):111-24
Wang et al. BMC Medicine 2018;16:17
Nightingale’s platform is an excellent tool to research the relationship between mother and child, and particularly to study metabolite transport between the two systems. Analysing blood, cord blood and urine enables studying the effects of the offspring’s short- and long-term metabolism and how that correlates with lifelong health. In addition, it enables studying pregnancy-related complications like pre-eclampsia and gestational diabetes.
All this is made possible by our extensive panels which contain several metabolites that support meaningful examination of pregnancy complications such as lipids, amino acids, glycolysis related metabolites and lipoprotein particles.
Taylor et al. Metabolites 2019;9(9):190
White et al. Diabetologia 2017;60(10):1903-12
Mills et al. BMC Medicine 2019;17(1):15